登录 | 注册    关注公众号  
搜索
 > 【TL1A】

TL1A信息

英文名称:Tumor necrosis factor superfamily member 15
中文名称:肿瘤坏死因子超家族成员15
靶点别称:VEGI192A,Vascular Endothelial Cell Growth Inhibitor,TNF Superfamily Ligand TL1A,TNFSF15,Tumor Necrosis Factor (Ligand) Superfamily, Member 15,Vascular Endothelial Growth Inhibitor-192A,VEGI,TL1A,Tumor Necrosis Factor Ligand 1B,TNLG1B,TNF Superfamily Member 15,Tumor Necrosis Factor Superfamily Member 15,TL1,TNF Ligand-Related Molecule 1,Tumor Necrosis Factor Ligand Superfamily Member 15,MGC129934,MGC129935
上市药物数量:0
临床药物数量:2
最高研发阶段:临床二期

TL1A产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
TLA-H5243
Human
Human TL1A / TNFSF15 Protein, His Tag (MALS verified)
 
评论(0)
 

TL1A 分子别名

TL1A, VEGI-251, TNFSF15

TL1A 分子背景

TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

TL1A 前沿进展

TL1A临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
PRA-023 PRA-023 临床二期 Prometheus Biosciences Inc 炎症性肠疾病, 间质性肺疾病, 溃疡性结肠炎, 弥漫性硬皮病, 克罗恩病 详情
PF-06480605 PF-06480605 临床二期 辉瑞制药有限公司 炎症性肠疾病, 溃疡性结肠炎, 克罗恩病 详情

消息提示

请输入您的联系方式,再点击提交!

确定